Generation of a Gene Corrected Human Isogenic IBMS-iPSC-014-C from Polycystic-kidney-disease Induced Pluripotent Stem Cell Line Using CRISPR/Cas9
Overview
Affiliations
We report the engendering an isogenic iPSC line from the IBMS-iPSC-014-05 with homozygous correction of the R803X, Chr4: 88989098C > T in PKD2, using CRISPR/Cas9 technology. The results from the isogenic control, IBMS-iPSC-014-05C, showed that mutation had been corrected, while maintaining normal morphology, pluripotency, and differentiation capacity into three germ layers.
Advances in CRISPR-Cas technology and its applications: revolutionising precision medicine.
Azeez S, Hamad R, Hamad B, Shekha M, Bergsten P Front Genome Ed. 2024; 6:1509924.
PMID: 39726634 PMC: 11669675. DOI: 10.3389/fgeed.2024.1509924.
Opportunities and Challenges of Human IPSC Technology in Kidney Disease Research.
Jia-Jung Lee , Lin C, Chen H, Hsieh P, Chiu Y, Chang J Biomedicines. 2022; 10(12).
PMID: 36551987 PMC: 9775669. DOI: 10.3390/biomedicines10123232.